is the use of drugs to kill cancer cells. Unlike
and surgery, which are localized treatments, chemotherapy is a systemic treatment, meaning the drugs travel throughout the entire body. This means chemotherapy may reach every cell in the body.
Many people with MDS do not require chemotherapy treatment other than supportive treatments, such as intermittent transfusions. However, at times chemotherapy may be required if no other options exist.
There are three combinations of chemotherapy drugs used to treat MDS. These combinations include:
Hypomethylating agents are drugs that slow down the growth of cells and include:
Immunomodulating drugs change the immune system and include:
Immunosupression agents suppress the immune system and include:
These agents have been used alone, in combination with other anticancer drugs, and with drugs in other categories, such as hematopoietic growth factors.
was initially used to treat MDS but has been replaced with lenalidomide (Revlimid) because of fewer side effects. Lenalidomide has been successful in reducing the number of transfusions needed by patients with low-grade MDS.
The only cure for MDS is a
stem cell transplant
(SCT). A SCT starts with high-dose
to kill the bone marrow and is then followed by an injection of healthy stem cells. The stem cells used can come from the blood or bone marrow.
There are two types of SCT. The less common one is called an autologous SCT, and occurs when the patient is injected with his own cells after high-dose chemotherapy. The more common method is called allogeneic and occurs when the patient gets donor cells after high-dose chemotherapy.
Low-dose chemotherapy treatment may briefly benefit certain classes of patients, such as the elderly, by exposing them to lower risk.
Side effects of chemotherapy for MDS are similar to those seen in
and other forms of
. The only unique aspect of treating MDS is the advanced age of the patients, which makes many side effects more likely and more severe.
Castro-Malaspina H, O’Reilly RJ. Aplastic anemia and the myelodysplastic syndromes. In
Harrison's Principles of Internal Medicine
. 14th ed. New York, NY: McGraw-Hill; 1998.
Chiodi S, Spinelli S, Ravera G, et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation.
Br J Haematol.
Drug Facts and Comparisons
. 56th ed. St. Louis, MO: Facts & Comparisons; 2001.
Léger CS, Nevill TJ. Hematopoietic stem cell transplantation: a primer for the primary care physician.
Last reviewed December 2013 by Mohei Abouzied, MD, FACP
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.